Author
Listed:
- Punnee Pitisuttithum
- Supachai Rerks-Ngarm
- Valai Bussaratid
- Jittima Dhitavat
- Wirach Maekanantawat
- Swangjai Pungpak
- Pravan Suntharasamai
- Sirivan Vanijanonta
- Sorachai Nitayapan
- Jaranit Kaewkungwal
- Michael Benenson
- Patricia Morgan
- Robert J O'Connell
- Jeffrey Berenberg
- Sanjay Gurunathan
- Donald P Francis
- Robert Paris
- Joseph Chiu
- Donald Stablein
- Nelson L Michael
- Jean-Louis Excler
- Merlin L Robb
- Jerome H Kim
Abstract
Background: A prime-boost vaccination regimen with ALVAC-HIV (vCP1521) administered intramuscularly at 0, 4, 12, and 24 weeks and gp120 AIDSVAX B/E at 12 and 24 weeks demonstrated modest efficacy of 31.2% for prevention of HIV acquisition in HIV-uninfected adults participating in a community-based efficacy trial in Thailand. Methodology/Principal Findings: Reactogenicity was recorded for 3 days following vaccination. Adverse events were monitored every 6 months for 3.5 years, during which pregnancy outcomes were recorded. Of the 16,402 volunteers, 69% of the participants reported an adverse event any time after the first dose. Only 32.9% experienced an AE within 30 days following any vaccination. Overall adverse event rates and attribution of relatedness did not differ between groups. The frequency of serious adverse events was similar in vaccine (14.3%) and placebo (14.9%) recipients (p = 0.33). None of the 160 deaths (85 in vaccine and 75 in placebo recipients, p = 0.43) was assessed as related to vaccine. The most common cause of death was trauma or traffic accident. Approximately 30% of female participants reported a pregnancy during the study. Abnormal pregnancy outcomes were experienced in 17.1% of vaccine and 14.6% (p = 0.13) of placebo recipients. When the conception occurred within 3 months (estimated) of a vaccination, the majority of these abnormal outcomes were spontaneous or elective abortions among 22.2% and 15.3% of vaccine and placebo pregnant recipients, respectively (p = 0.08). Local reactions occurred in 88.0% of vaccine and 61.0% of placebo recipients (p
Suggested Citation
Punnee Pitisuttithum & Supachai Rerks-Ngarm & Valai Bussaratid & Jittima Dhitavat & Wirach Maekanantawat & Swangjai Pungpak & Pravan Suntharasamai & Sirivan Vanijanonta & Sorachai Nitayapan & Jaranit , 2011.
"Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand,"
PLOS ONE, Public Library of Science, vol. 6(12), pages 1-10, December.
Handle:
RePEc:plo:pone00:0027837
DOI: 10.1371/journal.pone.0027837
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0027837. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.